Document:

NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”) AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A
LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.

 

CLASS
D UNIT PURCHASE WARRANT

 

NEXIEN
BIOPHARMA, INC.

 

Number
of Units:

Issue
Date:

Warrant
No. D-____

 

THIS
CLASS D UNIT PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ (the
“Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions
hereinafter set forth, at any time on or after the Issue Date (the “Initial Exercise Date”) and on or
prior to 5:00 p.m. Mountain Time on November 30, 2018 (the “Termination Date”) but not thereafter, to
subscribe for and purchase from NEXIEN BIOPHARMA, INC., a Delaware corporation (the “Company”), up to
______ Units each such Unit consisting of one share of Common Stock (the “Warrant Shares”) and one Class
E Common Stock Purchase Warrant (the “Class E Warrants”), which such Class E Warrant shall have an exercise
price equal to $2.00 per share and be exercisable through January 31, 2019. The purchase price of one Unit shall be equal to the
Exercise Price, as defined in Section 1(b).

 

Section
1. Exercise.

 

a)
Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any
time or times on or after the Initial Exercise Date and on or before the Termination Date, by delivery to the Company (or such
other office or agency of the Company as it may designate by notice in writing to the registered Holder at the address of the
Holder appearing on the books of the Company) of a facsimile or scanned copy of the duly executed Notice of Exercise Form annexed
hereto; and, within 3 Business Days of the date said Notice of Exercise is delivered to the Company, the Company shall have received
payment of the aggregate Exercise Price of the Units thereby purchased by wire transfer or cashier’s check drawn on a United
States bank. The Holder shall not be required to physically surrender this Warrant to the Company upon exercise. Partial exercises
of this Warrant resulting in purchases of a portion of the total number of Units available hereunder shall have the effect of
lowering the outstanding number of Units purchasable hereunder in an amount equal to the applicable number of Units purchased.
The Holder and the Company shall maintain records showing the number of Units purchased and the date of such purchases. The Company
shall deliver any objection to any Notice of Exercise Form within 2 Business Days of receipt of such notice. In the event of any
dispute or discrepancy, the records of the Holder shall be controlling and determinative in the absence of manifest error. The
Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph,
following the purchase of a portion of the Units hereunder, the number of Units available for purchase hereunder at any given
time may be less than the amount stated on the face hereof.

 

    	 

    	 

    

 

b)
Exercise Price. The exercise price per Unit under this Warrant shall be $1.00, subject to adjustment hereunder (the
“Exercise Price”).

 

c)
Mechanics of Exercise.

 

i.
Delivery of Certificates Upon Exercise. Certificates for Warrant Shares and Class E Warrants purchased hereunder shall
be delivered to the address specified by the Holder in the Notice of Exercise within the first 10 Business Days of the month following
the month in which the Notice of Exercise Form and payment of the aggregate Exercise Price is delivered to the Company (the “Unit
Delivery Date”). This Warrant shall be deemed to have been exercised on the date the Exercise Price is received
by the Company. The Units shall be deemed to have been issued, and Holder or any other person so designated to be named therein
shall be deemed to have become a holder of record of such Units for all purposes, as of the date the Warrant has been exercised
by payment to the Company of the Exercise Price and all taxes required to be paid by the Holder, if any, pursuant to Section
1(c)(v) prior to the issuance of such securities, have been paid.

 

ii.
Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request
of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the certificate or certificates representing
Units, deliver to Holder a new Warrant evidencing the rights of Holder to purchase the unpurchased Units called for by this Warrant,
which new Warrant shall in all other respects be identical with this Warrant.

 

iii.
Rescission Rights. If the Company fails to deliver to the Holder a certificate or the certificates representing the Units
pursuant to Section 1(c)(i) by the Unit Delivery Date, then, the Holder will have the right to rescind such exercise.

 

iv.
No Fractional Units or Scrip. No fractional Units or scrip representing fractional Units shall be issued upon the exercise
of this Warrant. As to any fraction of a Unit which Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole Unit.

 

v.
Charges, Taxes and Expenses. Issuance of certificates for Units shall be made without charge to the Holder for any issue
or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses shall
be paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names as may be directed
by the Holder; provided, however, that in the event certificates for Units are to be issued in a name other than the name
of the Holder, the Holder shall deliver to the Company the Assignment Form attached hereto duly executed by the Holder, and follow
the requirements set forth in Section 3(d). The Company may require, as a condition thereto, the payment of a sum sufficient
to reimburse it for any transfer tax incidental thereto.

 

    	Nexien BioPharma, Inc. Class D Unit Purchase Warrant – page 2

    	 

    

 

vi.
Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.

 

Section
2. Certain Adjustments.

 

a)
Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise make a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines
(including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by
reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares,
if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event and the number of Units issuable upon exercise of this Warrant shall be proportionately adjusted
such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section
2(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such
dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination
or re-classification.

 

b)
Calculations. All calculations under this Section 2 shall be made to the nearest cent or the nearest 1/100th of
a share, as the case may be. For purposes of this Section 2, the number of shares of Common Stock deemed to be issued and
outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued
and outstanding.

 

c)
Notice to Holder.

 

i.
Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 2,
the Company shall promptly mail/e-mail to the Holder a notice setting forth the Exercise Price after such adjustment and setting
forth a brief statement of the facts requiring such adjustment.

 

ii.
Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever
form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common
Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or
purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall
be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a
party, any sale or transfer of all or substantially all of the assets of the Company, of any compulsory share exchange whereby
the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary
dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed/emailed
to the Holder at its last address as it shall appear upon the Warrant Register of the Company, at least 5 Business Days prior
to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken
for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as
of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants
are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is
expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall
be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer or share exchange; provided that the failure to mail such notice or any defect therein or
in the mailing thereof shall not affect the validity of the corporate action required to be specified in such notice.

 

    	Nexien BioPharma, Inc. Class D Unit Purchase Warrant – page 3

    	 

    

 

 

The
Holder is entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the
event triggering such notice.

 

Section
3. Transfer of Warrant.

 

a)
Transferability. Subject to compliance with any applicable securities laws and the conditions set forth in Section 3(c)
hereof, this Warrant and all rights hereunder are transferable, in whole only, upon surrender of this Warrant at the principal
office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached
hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making
of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant in the
name of the assignee, and this Warrant shall promptly be cancelled. The Warrant, if properly assigned, may be exercised by a new
holder for the purchase of Units without having a new Warrant issued.

 

b)
Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose
(the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may
deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any
distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

 

c)
Transfer Restrictions. Any requested transfer of this Warrant, in whole only, shall be made by delivering to the Company
the Assignment Form and a Certificate of Accredited Investor Status completed by the proposed transferee(s). If the requested
transfer is approved by the Company in its sole discretion, a new Warrant shall be issued to the transferee(s).

 

Section
5. Miscellaneous.

 

a)
No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights or other rights
as a stockholder of the Company prior to the exercise hereof as set forth in Section 1(c)(i).

 

    	Nexien BioPharma, Inc. Class D Unit Purchase Warrant – page 4

    	 

    

 

b)
Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case
of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.

 

c)
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next
succeeding Business Day.

 

d)
Authorized Shares. The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized
and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of
any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full
authority to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary certificates
for the Class E Warrants and Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take
all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation
of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The
Company covenants that all Class E Warrants and Warrant Shares which may be issued upon the exercise of the purchase rights represented
by this Warrant will, upon exercise of the purchase rights represented by this Warrant, be duly authorized, validly issued, fully
paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other
than taxes in respect of any transfer occurring contemporaneously with such issue).

 

Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation,
amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the
terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all
such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.
Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above
the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may
be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares
upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions
or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform
its obligations under this Warrant.

 

    	Nexien BioPharma, Inc. Class D Unit Purchase Warrant – page 5

    	 

    

 

Before
taking any action which would result in an adjustment in the number of Warrant Shares and Class E Warrants for which this Warrant
is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto,
as may be necessary from any public regulatory body or bodies having jurisdiction thereof.

 

e)
Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be determined in accordance with the corporate laws of the State of Delaware.

 

f)
Restrictions. The Holder acknowledges that the Warrant Shares and Class E Warrants acquired upon the exercise of this Warrant,
if not registered, will have restrictions upon resale imposed by state and federal securities laws.

 

g)
Nonwaiver. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate
as a waiver of such right or otherwise prejudice Holder’s rights, powers or remedies, notwithstanding the fact that all
rights hereunder terminate on the Termination Date.

 

h)
Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company
shall be delivered to the Holder at his/her/its last known address appearing in the Warrant Register of the Company.

 

i)
Limitation of Liability. No provision hereof, in the absence of any affirmative action by Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of Holder, shall give rise to any liability
of Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by
the Company or by creditors of the Company.

 

j)
Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not
be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees
to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

 

k)
Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of all Holders from time to time of this Warrant and shall be
enforceable by the Holder or holder of Warrant Shares.

 

l)
Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company
and Holders holding at least a majority of the outstanding Class D Warrants.

 

m)
Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such
provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this Warrant.

 

n)
Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.

 

********************

 

(Signature
Page Follow)

 

    	Nexien BioPharma, Inc. Class D Unit Purchase Warrant – page 6

    	 

    

 

IN
WITNESS WHEREOF, the Company has caused this Class D Warrant to be executed by its officer thereunto duly authorized as of the
date first above indicated.

 

	 	NEXIEN
    BIOPHARMA, INC.
	 	 	             
	 	By:	 
	 	Name:	 
	 	Title:	 

 

    	Nexien BioPharma, Inc. Class D Unit Purchase Warrant – page 7

    	 

    

 

NOTICE
OF EXERCISE

 

	TO:
    	NEXIEN
    BIOPHARMA, INC.

 

	(1)	The
    undersigned hereby elects to purchase ________ Units of the Company pursuant to the terms of the attached Class D Warrant
    (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer
    taxes, if any.
	 	 
	(2)	Please
    issue a certificate or certificates representing said Warrant Shares and Class E Warrants [  ]  in the name of the
    undersigned     or  [  ] in such other name as is specified below:

 

	 	 
	 	 

 

	(3)	The
    undersigned acknowledges that neither the Warrant Shares nor the Class E Warrants have been registered under the Securities
    Act of 1933, as amended (the “1933 Act”). Accordingly, the undersigned acknowledges, represents, warrants and
    agrees as follows:

 

	 	a)	The
    Warrant Shares and Class E Warrants are being acquired for the undersigned’s own account for investment purposes only
    and with no view to their resale or other distribution of any kind, and no other person (except the spouse of the undersigned,
    if married) will own any interest therein.
	 	 	 
	 	b)	The
    undersigned will not sell or dispose of the Warrant Shares or Class E Warrants in violation of the 1933 Act, or any other
    applicable federal or state securities laws.
	 	 	 
	 	c)	The
    undersigned agrees that the Company may, without liability for its good faith actions, place legend restrictions upon the
    Warrant Shares and Class E Warrants and issue “stop transfer” instructions requiring compliance with applicable
    securities laws and the terms of the Class D Warrant.
	 	 	 
	 	d)	The
    undersigned represents, warrants and agrees, as of the date of this Agreement to Exchange, that the undersigned continues
    to be an “accredited investor” as defined in the rules and regulations promulgated under the 1933 Act.

 

	 	 	 
	Name
    of Holder (Printed)	 	Signature
	 

         

        
	 	 

         

        

	Name
                                         of Holder’s Spouse (if name appears on this Warrant)

         

         
	 	Title
                                         (if applicable)

         

         

	Date	 	Address

         

         

 

    	Nexien BioPharma, Inc. Class D Unit Purchase Warrant – page 8

    	 

    

 

ASSIGNMENT
FORM

 

(To
assign the foregoing warrant, execute this form and supply required information.

Do
not use this form to exercise the warrant.)

 

FOR
VALUE RECEIVED, [____] all of or [_______] Warrants of the foregoing Warrant and all rights evidenced thereby are hereby assigned
to

 

________________________________________
____ whose address is

 

_____________________________________________________________________________________________

 

_____________________________________________________________________________________________ 

 

	 	 	 
	Name
    of Holder (Printed)	 	Signature
	 

         

        
	 	 

         

        

	Name
                                         of Holder’s Spouse (if name appears on this Warrant)

         

         
	 	Title
                                         (if applicable)

         

         

	Date	 	Address

         

         

 

    	Nexien BioPharma, Inc. Class D Unit Purchase Warrant – page 9

    	 

    

 

CERTIFICATE
OF ACCREDITED INVESTOR STATUS

 

Except
as may be indicated by the undersigned below, the undersigned is an individual “accredited investor,” as that term
is defined in Regulation D under the Securities Act of 1933, as amended (the “Act”). The undersigned has checked
the box below indicating the basis on which it is representing its status as an “accredited investor”:

 

	[  ]	a
    bank as defined in Section 3(a)(2) of the Act, or any savings and loan association or other institution as defined in Section
    3(a)(5)(A) of the Act whether acting in its individual or fiduciary capacity; a broker or dealer registered pursuant to Section
    15 of the Securities Exchange Act of 1934; an insurance company as defined in Section 2(a)(13) of the Act; an investment company
    registered under the Investment Company Act of 1940 or a business development company as defined in Section 2(a)(48) of that
    act; a small business investment company licensed by the U.S. Small Business Administration under Section 301(c) or (d) of
    the Small Business Investment Act of 1958; a plan established and maintained by a state, its political subdivisions, or any
    agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, if such plan has total
    assets in excess of $5,000,000; an employee benefit plan within the meaning of the Employee Retirement Income Security Act
    of 1974, if the investment decision is made by a plan fiduciary, as defined in Section 3(21) of such act, which is either
    a bank, savings and loan association, insurance company, or registered investment adviser, or if the employee benefit plan
    has total assets in excess of $5,000,000 or, if a self-directed plan, with investment decisions made solely by persons that
    are “accredited investors”;
	 	 
	[  ]	a
    private business development company as defined in Section 202(a)(22) of the Investment Advisers Act of 1940;
	 	 
	[  ]	an
    organization described in Section 501(c)(3) of the Internal Revenue Code, corporation, Massachusetts or similar business trust,
    or partnership, not formed for the specific purpose of acquiring the securities offered, with total assets in excess of $5,000,000;
	 	 
	[  ]	a
    natural person whose individual net worth, or joint net worth with the undersigned’s spouse, excluding the “net
    value” of his or her primary residence, at the time of this purchase exceeds $1,000,000 and having no reason to believe
    that net worth will not remain in excess of $1,000,000 for the foreseeable future, with “net value” for such purposes
    being the fair value of the residence less any mortgage indebtedness or other obligation secured by the residence, but subtracting
    such indebtedness or obligation only if it is a liability already considered in calculating net worth;
	 	 
	[  ]	a
    natural person who had an individual income in excess of $200,000 in each of the two most recent years or joint income with
    the undersigned’s spouse in excess of $300,000 in each of those years and has a reasonable expectation of reaching the
    same income level in the current year;
	 	 
	[  ]	a
    trust with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the securities offered,
    whose purchase is directed by a person who has such knowledge and experience in financial and business matters that he is
    capable of evaluating the merits and risks of the prospective investment; or
	 	 
	[  ]	an
    entity in which all of the equity holders are “accredited investors” by virtue of their meeting one or more of
    the above standards.
	 	 
	[  ]	an
    individual who is a director or executive officer of Nexien BioPharma, Inc.

 

    	Nexien BioPharma, Inc. Class D Unit Purchase Warrant – page 10

    	 

    

 

IN
WITNESS WHEREOF, the undersigned has executed this Certificate of Accredited Investor Status effective as of __________________,
2018.

 

	Date:
    		 	 
	 	 	 	Subscriber
    Name (Printed)
	 	 	 	 
	 	 	 	By:	      
	 	 	 	Name:	 
	 	 	 	Title:	 

 

    	Nexien BioPharma, Inc. Class D Unit Purchase Warrant – page 11NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”) AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A
LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.

 

CLASS
E SHARE PURCHASE WARRANT

 

NEXIEN
BIOPHARMA, INC.

 

Number
of Shares:

Issue
Date:

Warrant
No. E-____

 

THIS
CLASS E SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ (the
“Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions
hereinafter set forth, at any time on or after the Issue Date (the “Initial Exercise Date”) and on or
prior to 5:00 p.m. Mountain Time on January 31, 2019 (the “Termination Date”) but not thereafter, to
subscribe for and purchase from NEXIEN BIOPHARMA, INC., a Delaware corporation (the “Company”), up to
______ shares of Common Stock (the “Warrant Shares”). The purchase price of one Warrant Share shall
be equal to the Exercise Price, as defined in Section 1(b).

 

Section
1. Exercise.

 

a)
Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any
time or times on or after the Initial Exercise Date and on or before the Termination Date, by delivery to the Company (or such
other office or agency of the Company as it may designate by notice in writing to the registered Holder at the address of the
Holder appearing on the books of the Company) of a facsimile or scanned copy of the duly executed Notice of Exercise Form annexed
hereto; and, within 3 Business Days of the date said Notice of Exercise is delivered to the Company, the Company shall have received
payment of the aggregate Exercise Price of the shares thereby purchased by wire transfer or cashier’s check drawn on a United
States bank. The Holder shall not be required to physically surrender this Warrant to the Company upon exercise. Partial exercises
of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect
of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant
Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date
of such purchases. The Company shall deliver any objection to any Notice of Exercise Form within 2 Business Days of receipt of
such notice. In the event of any dispute or discrepancy, the records of the Holder shall be controlling and determinative in the
absence of manifest error. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason
of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant
Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

 

    	 

    	 

    

 

b)
Exercise Price. The exercise price per Warrant Share under this Warrant shall be $2.00, subject to adjustment hereunder
(the “Exercise Price”).

 

c)
Mechanics of Exercise.

 

i.
Delivery of Certificates Upon Exercise. Certificates for Warrant Shares purchased hereunder shall be delivered to the address
specified by the Holder in the Notice of Exercise within the first 10 Business Days of the month following the month in which
the Notice of Exercise Form and payment of the aggregate Exercise Price is delivered to the Company (the “Share Delivery
Date”). This Warrant shall be deemed to have been exercised on the date the Exercise Price is received by the Company.
The Warrant Shares shall be deemed to have been issued, and Holder or any other person so designated to be named therein shall
be deemed to have become a holder of record of such Warrant Shares for all purposes, as of the date the Warrant has been exercised
by payment to the Company of the Exercise Price and all taxes required to be paid by the Holder, if any, pursuant to Section
1(c)(v) prior to the issuance of such shares, have been paid.

 

ii.
Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request
of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the certificate or certificates representing
Warrant Shares, deliver to Holder a new Warrant evidencing the rights of Holder to purchase the unpurchased Warrant Shares called
for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

 

iii.
Rescission Rights. If the Company fails to deliver to the Holder a certificate or the certificates representing the Warrant
Shares pursuant to Section 1(c)(i) by the Warrant Share Delivery Date, then, the Holder will have the right to rescind
such exercise.

 

iv.
No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.

 

v.
Charges, Taxes and Expenses. Issuance of certificates for Warrant Shares shall be made without charge to the Holder for
any issue or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses
shall be paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names as may
be directed by the Holder; provided, however, that in the event certificates for Warrant Shares are to be issued in a name
other than the name of the Holder, the Holder shall deliver to the Company the Assignment Form attached hereto duly executed by
the Holder, and follow the requirements set forth in Section 3(d). The Company may require, as a condition thereto, the
payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.

 

    	Nexien BioPharma, Inc. Class E Share Purchase Warrant – page 2

    	 

    

 

vi.
Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.

 

Section
2. Certain Adjustments.

 

a)
Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise make a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines
(including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by
reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares,
if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event and the number of Warrant Shares issuable upon exercise of this Warrant shall be proportionately
adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section
2(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such
dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination
or re-classification.

 

b)
Calculations. All calculations under this Section 2 shall be made to the nearest cent or the nearest 1/100th of
a share, as the case may be. For purposes of this Section 2, the number of shares of Common Stock deemed to be issued and
outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued
and outstanding.

 

c)
Notice to Holder.

 

i.
Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 2,
the Company shall promptly mail/e-mail to the Holder a notice setting forth the Exercise Price after such adjustment and setting
forth a brief statement of the facts requiring such adjustment.

 

ii.
Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever
form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common
Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or
purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall
be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a
party, any sale or transfer of all or substantially all of the assets of the Company, of any compulsory share exchange whereby
the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary
dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be mailed/emailed
to the Holder at its last address as it shall appear upon the Warrant Register of the Company, at least 5 Business Days prior
to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken
for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as
of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants
are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is
expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall
be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer or share exchange; provided that the failure to mail such notice or any defect therein or
in the mailing thereof shall not affect the validity of the corporate action required to be specified in such notice.

 

    	Nexien BioPharma, Inc. Class E Share Purchase Warrant – page 3

    	 

    

 

The
Holder is entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the
event triggering such notice.

 

Section
3. Transfer of Warrant.

 

a)
Transferability. Subject to compliance with any applicable securities laws and the conditions set forth in Section 3(c)
hereof, this Warrant and all rights hereunder are transferable, in whole only, upon surrender of this Warrant at the principal
office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached
hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making
of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant in the
name of the assignee, and this Warrant shall promptly be cancelled. The Warrant, if properly assigned, may be exercised by a new
holder for the purchase of Warrant Shares without having a new Warrant issued.

 

b)
Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose
(the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may
deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any
distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

 

c)
Transfer Restrictions. Any requested transfer of this Warrant, in whole only, shall be made by delivering to the Company
the Assignment Form and a Certificate of Accredited Investor Status completed by the proposed transferee(s). If the requested
transfer is approved by the Company in its sole discretion, a new Warrant shall be issued to the transferee(s).

 

Section
5. Miscellaneous.

 

a)
No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights or other rights
as a stockholder of the Company prior to the exercise hereof as set forth in Section 1(c)(i).

 

    	Nexien BioPharma, Inc. Class E Share Purchase Warrant – page 4

    	 

    

 

b)
Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant
Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case
of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation,
in lieu of such Warrant or stock certificate.

 

c)
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next
succeeding Business Day.

 

d)
Authorized Shares. The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized
and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of
any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full
authority to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary certificates
for the Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable
action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable
law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant, be duly authorized, validly issued, fully paid and nonassessable and free
from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer
occurring contemporaneously with such issue).

 

Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation,
amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the
terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all
such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.
Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Shares or Warrant Shares
above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action
as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant
Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions
or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform
its obligations under this Warrant.

 

    	Nexien BioPharma, Inc. Class E Share Purchase Warrant – page 5

    	 

    

 

Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or
in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be
necessary from any public regulatory body or bodies having jurisdiction thereof.

 

e)
Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be determined in accordance with the corporate laws of the State of Delaware.

 

f)
Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered,
will have restrictions upon resale imposed by state and federal securities laws.

 

g)
Nonwaiver. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate
as a waiver of such right or otherwise prejudice Holder’s rights, powers or remedies, notwithstanding the fact that all
rights hereunder terminate on the Termination Date.

 

h)
Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company
shall be delivered to the Holder at his/her/its last known address appearing in the Warrant Register of the Company.

 

i)
Limitation of Liability. No provision hereof, in the absence of any affirmative action by Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of Holder, shall give rise to any liability
of Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by
the Company or by creditors of the Company.

 

j)
Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not
be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees
to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

 

k)
Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of all Holders from time to time of this Warrant and shall be
enforceable by the Holder or holder of Warrant Shares.

 

l)
Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company
and Holders holding at least a majority of the outstanding Class E Warrants.

 

m)
Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such
provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this Warrant.

 

n)
Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.

 

********************

 

(Signature
Page Follow)

 

    	Nexien BioPharma, Inc. Class E Share Purchase Warrant – page 6

    	 

    

 

IN
WITNESS WHEREOF, the Company has caused this Class E Warrant to be executed by its officer thereunto duly authorized as of the
date first above indicated.

 

	 	NEXIEN
    BIOPHARMA, INC.
	 	 	             
	 	By:
    	 
	 	Name:
    	 
	 	Title:
    	 

 

    	Nexien BioPharma, Inc. Class E Share Purchase Warrant – page 7

    	 

    

 

NOTICE
OF EXERCISE

 

	TO:
    	NEXIEN
    BIOPHARMA, INC.

 

	(1)	The
    undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Class E
    Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable
    transfer taxes, if any.
	 	 
	(2)	Please
    issue a certificate or certificates representing said Warrant Shares [  ] in the name of the undersigned or [  ]
    in such other name as is specified below:

 

	 	 
	 	 

 

	(3)	The
    undersigned acknowledges that the Warrant Shares have not been registered under the Securities Act of 1933, as amended (the
    “1933 Act”). Accordingly, the undersigned acknowledges, represents, warrants and agrees as follows:

 

	 	a)	The
    Warrant Shares are being acquired for the undersigned’s own account for investment purposes only and with no view to
    their resale or other distribution of any kind, and no other person (except the spouse of the undersigned, if married) will
    own any interest therein.
	 	 	 
	 	b)	The
    undersigned will not sell or dispose of the Warrant Shares in violation of the 1933 Act, or any other applicable federal or
    state securities laws.
	 	 	 
	 	c)	The
    undersigned agrees that the Company may, without liability for its good faith actions, place legend restrictions upon the
    Warrant Shares and issue “stop transfer” instructions requiring compliance with applicable securities laws and
    the terms of the Class E Warrant.
	 	 	 
	 	d)	The
    undersigned represents, warrants and agrees, as of the date of this Agreement to Exchange, that the undersigned continues
    to be an “accredited investor” as defined in the rules and regulations promulgated under the 1933 Act.

 

	 	 	 
	Name
    of Holder (Printed)	 	Signature
	 

         

        
	 	 

         

        

	Name
                                         of Holder’s Spouse (if name appears on this Warrant)

         

         
	 	Title
                                         (if applicable)

         

         

	Date	 	Address

         

         

 

    	Nexien BioPharma, Inc. Class E Share Purchase Warrant – page 8

    	 

    

 

ASSIGNMENT
FORM

 

(To
assign the foregoing warrant, execute this form and supply required information.

Do
not use this form to exercise the warrant.)

 

FOR
VALUE RECEIVED, [____] all of or [_______] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned
to

 

________________________________________
____ whose address is

 

______________________________________________________________________________________________

 

______________________________________________________________________________________________ 

 

	 	 	 
	Name
    of Holder (Printed)	 	Signature
	 

         

        
	 	 

         

        

	Name
                                         of Holder’s Spouse (if name appears on this Warrant)

         

         
	 	Title
                                         (if applicable)

         

         

	Date	 	Address

         

         

 

    	Nexien BioPharma, Inc. Class E Share Purchase Warrant – page 9

    	 

    

 

CERTIFICATE
OF ACCREDITED INVESTOR STATUS

 

Except
as may be indicated by the undersigned below, the undersigned is an individual “accredited investor,” as that term
is defined in Regulation D under the Securities Act of 1933, as amended (the “Act”). The undersigned has checked
the box below indicating the basis on which it is representing its status as an “accredited investor”:

 

	[  ]	a
    bank as defined in Section 3(a)(2) of the Act, or any savings and loan association or other institution as defined in Section
    3(a)(5)(A) of the Act whether acting in its individual or fiduciary capacity; a broker or dealer registered pursuant to Section
    15 of the Securities Exchange Act of 1934; an insurance company as defined in Section 2(a)(13) of the Act; an investment company
    registered under the Investment Company Act of 1940 or a business development company as defined in Section 2(a)(48) of that
    act; a small business investment company licensed by the U.S. Small Business Administration under Section 301(c) or (d) of
    the Small Business Investment Act of 1958; a plan established and maintained by a state, its political subdivisions, or any
    agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, if such plan has total
    assets in excess of $5,000,000; an employee benefit plan within the meaning of the Employee Retirement Income Security Act
    of 1974, if the investment decision is made by a plan fiduciary, as defined in Section 3(21) of such act, which is either
    a bank, savings and loan association, insurance company, or registered investment adviser, or if the employee benefit plan
    has total assets in excess of $5,000,000 or, if a self-directed plan, with investment decisions made solely by persons that
    are “accredited investors”;
	 	 
	[  ]	a
    private business development company as defined in Section 202(a)(22) of the Investment Advisers Act of 1940;
	 	 
	[  ]	an
    organization described in Section 501(c)(3) of the Internal Revenue Code, corporation, Massachusetts or similar business trust,
    or partnership, not formed for the specific purpose of acquiring the securities offered, with total assets in excess of $5,000,000;
	 	 
	[  ]	a
    natural person whose individual net worth, or joint net worth with the undersigned’s spouse, excluding the “net
    value” of his or her primary residence, at the time of this purchase exceeds $1,000,000 and having no reason to believe
    that net worth will not remain in excess of $1,000,000 for the foreseeable future, with “net value” for such purposes
    being the fair value of the residence less any mortgage indebtedness or other obligation secured by the residence, but subtracting
    such indebtedness or obligation only if it is a liability already considered in calculating net worth;
	 	 
	[  ]	a
    natural person who had an individual income in excess of $200,000 in each of the two most recent years or joint income with
    the undersigned’s spouse in excess of $300,000 in each of those years and has a reasonable expectation of reaching the
    same income level in the current year;
	 	 
	[  ]	a
    trust with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the securities offered,
    whose purchase is directed by a person who has such knowledge and experience in financial and business matters that he is
    capable of evaluating the merits and risks of the prospective investment; or
	 	 
	[  ]	an
    entity in which all of the equity holders are “accredited investors” by virtue of their meeting one or more of
    the above standards.
	 	 
	[  ]	an
    individual who is a director or executive officer of Nexien BioPharma, Inc.

 

    	Nexien BioPharma, Inc. Class E Share Purchase Warrant – page 10

    	 

    

 

IN
WITNESS WHEREOF, the undersigned has executed this Certificate of Accredited Investor Status effective as of __________________,
201__.

 

	Date:	 	 	 
	 	 	 	Subscriber
    Name (Printed)
	 	 	 	 	      
	 	 	 	By:	 
	 	 	 	Name:	 
	 	 	 	Title:	 

 

    	Nexien BioPharma, Inc. Class E Share Purchase Warrant – page 11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}]]